-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, the research and development of new anti-tumor drugs at home and abroad has been quite h.
According to incomplete statistics, among the new drugs approved by the drug regulatory authorities in the first half of 2022 in China, the United States and Europe, 26 new drugs are still mainly anti-tumor drugs, among which China has approved more tumor dru.
It is understood that many domestic pharmaceutical companies, such as Hengrui, BeiGene, Fosun Pharma, CSPC, and Chia Tai Tianqing, are actively deploying anti-tumor drugs, and have launched innovative research and development for different targe.
With the efforts of these pharmaceutical companies and a series of policies launched by China to promote the launch of new tumor drugs, the launch of new anti-tumor drugs, especially the approval of self-developed domestic innovative drugs, is accelerati.
Data shows that in the first half of this year, 30 innovative drugs were approved for marketing in China, of which 15 were anti-tumor drugs, accounting for 50%, involving gastric cancer, bile duct cancer, cervical cancer, lung cancer, Hodgkin lymphoma, Leukemia, prostate cancer,e.
It is worth noting that the Insight database predicts that there are still 8 blockbuster new anti-tumor drugs that are expected to be approved for listing in the second half of the year, including Betta Pharmaceuticals' befotinib, Qilu Pharmaceutical's Iluac, and Yingli Pharmaceutical's developme.
The Limplis et .
It is worth noting that among the 8 new anti-tumor drugs, 5 of them are indicated for non-small cell lung canc.
It is understood that non-small cell lung cancer accounts for 80%-85% of all lung cance.
Among the innovative drugs approved in 2021, there are 4 new drugs with indications for non-small cell lung cancer, and among the innovative anti-tumor drugs approved in the first half of this year, there are also two for the treatment of non-small cell lung canc.
In the second half of the year, the indications of the 5 models that are expected to be approved for marketing involve non-small cell lung cancer, namely befotinib from Betta Pharmaceuticals, and the third-generation small molecule EGFR-TKI Rui from CSPC/Beida Pharmaceutica.
Zetinib, Qilu Pharma's Iluac, Eli Lilly's Selpercatinib, and Takeda Pharma's Mobocertin.
Among them, Betta Pharmaceuticals' befotinib is a third-generation epidermal growth factor receptor EGFR tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutati.
In March 2021, Betta Pharmaceuticals submitted a listing application in China for the treatment of locally advanced or metastatic non-small cell lung cancer with T790M mutation after EGFR-TKI resistan.
The Clove Garden Insight database shows that the drug's marketing application has been reviewed and approval is immine.
CSPC/Beyerda Pharmaceuticals is also a third-generation small molecule EGFR-TKI for non-small cell lung canc.
Rezetinib is an irreversible and highly selective third-generation small-molecule EGFR-TKI for the treatment of non-small cell lung canc.
Molecular epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), studies have shown that it has obvious anti-tumor activity and good safe.
From the published data, the efficacy and safety of the drug, Similar to almetinib and osimertin.
In May 2021, Beyerda Pharmaceuticals has submitted a new drug marketing application to the State Food and Drug Administrati.
Qilu Pharmaceutical applied for listing Iluak, a new ALK/ROS1 inhibitor independently developed by Qilu Pharmaceuticals, which can inhibit the activity of wild-type ALK kinases of different fusion types and ALK inhibitor-resistant mutations, and can effectively inhibit ROS1 kinases of different fusion typ.
activi.
Qilu Pharmaceutical submitted a new drug marketing application for the drug in July 202 The indication for this marketing application is locally advanced or ALK-positive ALK-positive patients with disease progression after previous crizotinib treatment or intolerant to crizotin.
metastatic non-small cell lung cancer
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
According to incomplete statistics, among the new drugs approved by the drug regulatory authorities in the first half of 2022 in China, the United States and Europe, 26 new drugs are still mainly anti-tumor drugs, among which China has approved more tumor dru.
It is understood that many domestic pharmaceutical companies, such as Hengrui, BeiGene, Fosun Pharma, CSPC, and Chia Tai Tianqing, are actively deploying anti-tumor drugs, and have launched innovative research and development for different targe.
With the efforts of these pharmaceutical companies and a series of policies launched by China to promote the launch of new tumor drugs, the launch of new anti-tumor drugs, especially the approval of self-developed domestic innovative drugs, is accelerati.
Data shows that in the first half of this year, 30 innovative drugs were approved for marketing in China, of which 15 were anti-tumor drugs, accounting for 50%, involving gastric cancer, bile duct cancer, cervical cancer, lung cancer, Hodgkin lymphoma, Leukemia, prostate cancer,e.
It is worth noting that the Insight database predicts that there are still 8 blockbuster new anti-tumor drugs that are expected to be approved for listing in the second half of the year, including Betta Pharmaceuticals' befotinib, Qilu Pharmaceutical's Iluac, and Yingli Pharmaceutical's developme.
The Limplis et .
It is worth noting that among the 8 new anti-tumor drugs, 5 of them are indicated for non-small cell lung canc.
It is understood that non-small cell lung cancer accounts for 80%-85% of all lung cance.
Among the innovative drugs approved in 2021, there are 4 new drugs with indications for non-small cell lung cancer, and among the innovative anti-tumor drugs approved in the first half of this year, there are also two for the treatment of non-small cell lung canc.
In the second half of the year, the indications of the 5 models that are expected to be approved for marketing involve non-small cell lung cancer, namely befotinib from Betta Pharmaceuticals, and the third-generation small molecule EGFR-TKI Rui from CSPC/Beida Pharmaceutica.
Zetinib, Qilu Pharma's Iluac, Eli Lilly's Selpercatinib, and Takeda Pharma's Mobocertin.
Among them, Betta Pharmaceuticals' befotinib is a third-generation epidermal growth factor receptor EGFR tyrosine kinase inhibitor (EGFR-TKI) targeting T790M mutati.
In March 2021, Betta Pharmaceuticals submitted a listing application in China for the treatment of locally advanced or metastatic non-small cell lung cancer with T790M mutation after EGFR-TKI resistan.
The Clove Garden Insight database shows that the drug's marketing application has been reviewed and approval is immine.
CSPC/Beyerda Pharmaceuticals is also a third-generation small molecule EGFR-TKI for non-small cell lung canc.
Rezetinib is an irreversible and highly selective third-generation small-molecule EGFR-TKI for the treatment of non-small cell lung canc.
Molecular epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), studies have shown that it has obvious anti-tumor activity and good safe.
From the published data, the efficacy and safety of the drug, Similar to almetinib and osimertin.
In May 2021, Beyerda Pharmaceuticals has submitted a new drug marketing application to the State Food and Drug Administrati.
Qilu Pharmaceutical applied for listing Iluak, a new ALK/ROS1 inhibitor independently developed by Qilu Pharmaceuticals, which can inhibit the activity of wild-type ALK kinases of different fusion types and ALK inhibitor-resistant mutations, and can effectively inhibit ROS1 kinases of different fusion typ.
activi.
Qilu Pharmaceutical submitted a new drug marketing application for the drug in July 202 The indication for this marketing application is locally advanced or ALK-positive ALK-positive patients with disease progression after previous crizotinib treatment or intolerant to crizotin.
metastatic non-small cell lung cancer
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
